|
|
The Proven Performance of the S-Stent Platform on a new generation delivery system
that provides great trackability for tortuous vessels and crossability for tight lesions
Key Features and Benefists
Open cell design with Quadrature Link™ |
Excellent side branch Access
Excellent flexibility |
Low stent profile |
Good crossability |
New hydrophilic coating
Upgraded balloon material |
High deliverability |
Gazelle provides:
Tiger™ Stent Delivery System
Key features and benefists
Soft and multiple folding balloon material maintains low stent profile and ensures uniform expansion |
Enhanced crossability trackability |
Slip-X hydrophilic coating |
Enhanced tracability through tortuous vessels |
Swaged markers |
Improved stent placement visibility |
Tapered Power Stylet design |
Excellent kink resistance |
Clinical evidence
S-Stent Multicenter Safety And Efficacy Trial
Prospective multicenter feasibilty study performed in 4 centres, N=120
Primary Endpoint: MACE at 30 days.
Secondary Endpoint: Acute and long term angiographic outcome after Biosensors S-Stent implantation. |
Results:
MACE at 6 months: 1,68%
Angiographic restenosis rate at 6 months: 16,5%
TLR at 6 monhts: 10%
Stent deployment was successful in 100% of lesions. |
Coclusion:
The S-Stent has uniform expanding property and excellent deliverability. |
S-Stent Japan Clinical Trial
A non-randomized prospective study.
N=105.
Primary EndPoint: 6 monhts QCA, 6 months Binary Restenosis, 6 months MACE. |
Results:
MACE at 30 days: 0,0%
MACE at 6 months:5,7%
Binary Restenosis at 6 months: 10,9%
QCA at 6 months: 29,5% |
Conclusion:
Safety and efficacy of S-Stent demonstrated at 6 months. |
|
General Information
Back to Products Main Page